Literature DB >> 22995883

Association between periprocedural bleeding and long-term outcomes following percutaneous coronary intervention in older patients.

Sunil V Rao1, David Dai, Sumeet Subherwal, William S Weintraub, Ralph S Brindis, John C Messenger, Renato D Lopes, Eric D Peterson.   

Abstract

OBJECTIVES: The authors sought to describe the association between post-procedural bleeding and long-term recurrent bleeding, major adverse cardiac events (MACE), and mortality among older patients undergoing percutaneous coronary intervention (PCI).
BACKGROUND: Bleeding complications after PCI are associated with an increased risk for acute morbidity and long-term mortality, but the association of these bleeding complications with other events is unknown.
METHODS: Patients entered into the National Cardiovascular Data Registry (NCDR) CathPCI Registry (n = 461,311; 946 sites) from January 2004 to December 2008 were linked with claims from the Centers for Medicare & Medicaid Services and grouped according to in-hospital post-PCI bleeding. The association between post-PCI bleeding and 1-, 12-, and 30-month readmission for bleeding, MACE, and all-cause mortality was examined with Cox regression that included patient and procedural characteristics using no bleeding as the reference.
RESULTS: Overall, 3.1% (n = 14,107) of patients experienced post-PCI bleeding. Patients who bled were older, more often female, had more medical comorbidities, less often received bivalirudin, and more often underwent PCI via the femoral approach. After adjustment, bleeding after the index procedure was significantly associated with readmission for bleeding (adjusted hazard ratios [95% confidence interval]: 1 month, 1.54 [1.42 to 1.67]; 12 months, 1.52 [1.40 to 1.66]; 30 months, 1.29 [1.11 to 1.50]), MACE (1 month, 1.11 [1.07 to 1.15]; 12 months, 1.17 [1.13 to 1.21]; 30 months, 1.12 [1.06 to 1.19]) and all-cause mortality (1 month, 1.32 [1.26 to 1.38]; 12 months, 1.33 [1.27 to 1.40]); 30 months, 1.22 [1.15 to 1.30]).
CONCLUSIONS: Post-PCI bleeding complications are associated with an increased risk for short- and long-term recurrent bleeding, MACE, and all-cause mortality. These data underscore the prognostic importance of periprocedural bleeding and the need for identifying strategies to reduce long-term bleeding risk among patients undergoing PCI.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22995883      PMCID: PMC3908902          DOI: 10.1016/j.jcin.2012.05.010

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  28 in total

Review 1.  Anticoagulant therapy for percutaneous coronary intervention.

Authors:  Sunil V Rao; E Magnus Ohman
Journal:  Circ Cardiovasc Interv       Date:  2010-02-01       Impact factor: 6.546

Review 2.  Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice.

Authors:  Brendan J Doyle; Charanjit S Rihal; Dennis A Gastineau; David R Holmes
Journal:  J Am Coll Cardiol       Date:  2009-06-02       Impact factor: 24.094

3.  Contemporary mortality risk prediction for percutaneous coronary intervention: results from 588,398 procedures in the National Cardiovascular Data Registry.

Authors:  Eric D Peterson; David Dai; Elizabeth R DeLong; J Matthew Brennan; Mandeep Singh; Sunil V Rao; Richard E Shaw; Matthew T Roe; Kalon K L Ho; Lloyd W Klein; Ronald J Krone; William S Weintraub; Ralph G Brindis; John S Rumsfeld; John A Spertus
Journal:  J Am Coll Cardiol       Date:  2010-05-04       Impact factor: 24.094

4.  Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.

Authors:  Freek W A Verheugt; Steven R Steinhubl; Martial Hamon; Harald Darius; Philippe Gabriel Steg; Marco Valgimigli; Steven P Marso; Sunil V Rao; Anthony H Gershlick; A Michael Lincoff; Roxana Mehran; Gregg W Stone
Journal:  JACC Cardiovasc Interv       Date:  2011-02       Impact factor: 11.195

5.  Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.

Authors:  Shamir R Mehta; Jean-Pierre Bassand; Susan Chrolavicius; Rafael Diaz; John W Eikelboom; Keith A A Fox; Christopher B Granger; Sanjit Jolly; Campbell D Joyner; Hans-Jurgen Rupprecht; Petr Widimsky; Rizwan Afzal; Janice Pogue; Salim Yusuf
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

6.  Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention.

Authors:  Steven P Marso; Amit P Amin; John A House; Kevin F Kennedy; John A Spertus; Sunil V Rao; David J Cohen; John C Messenger; John S Rumsfeld
Journal:  JAMA       Date:  2010-06-02       Impact factor: 56.272

7.  Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis.

Authors:  Gregory Ducrocq; Joshua S Wallace; Gabriel Baron; Philippe Ravaud; Mark J Alberts; Peter W F Wilson; Erik Magnus Ohman; Danielle M Brennan; Ralph B D'Agostino; Deepak L Bhatt; Philippe Gabriel Steg
Journal:  Eur Heart J       Date:  2010-02-24       Impact factor: 29.983

8.  Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial.

Authors:  Roxana Mehran; Alexandra J Lansky; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; S Chiu Wong; Eugenia Nikolsky; Louise Gambone; Lynn Vandertie; Helen Parise; George D Dangas; Gregg W Stone
Journal:  Lancet       Date:  2009-08-28       Impact factor: 79.321

9.  Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry.

Authors:  Sunil V Rao; Fang-Shu Ou; Tracy Y Wang; Matthew T Roe; Ralph Brindis; John S Rumsfeld; Eric D Peterson
Journal:  JACC Cardiovasc Interv       Date:  2008-08       Impact factor: 11.195

10.  Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry.

Authors:  Sameer K Mehta; Andrew D Frutkin; Jason B Lindsey; John A House; John A Spertus; Sunil V Rao; Fang-Shu Ou; Matthew T Roe; Eric D Peterson; Steven P Marso
Journal:  Circ Cardiovasc Interv       Date:  2009-05-08       Impact factor: 6.546

View more
  17 in total

1.  Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.

Authors:  Pallav Garg; Benjamin Z Galper; David J Cohen; Robert W Yeh; Laura Mauri
Journal:  Am Heart J       Date:  2014-11-10       Impact factor: 4.749

2.  Timing and Causes of Unplanned Readmissions After Percutaneous Coronary Intervention: Insights From the Nationwide Readmission Database.

Authors:  Chun Shing Kwok; Binita Shah; Jassim Al-Suwaidi; David L Fischman; Lene Holmvang; Chadi Alraies; Rodrigo Bagur; Vinayak Nagaraja; Muhammad Rashid; Mohamed Mohamed; Glen P Martin; Evan Kontopantelis; Tim Kinnaird; Mamas Mamas
Journal:  JACC Cardiovasc Interv       Date:  2019-03-27       Impact factor: 11.195

3.  Relationship Between Operator Volume and Long-Term Outcomes After Percutaneous Coronary Intervention.

Authors:  Alexander C Fanaroff; Pearl Zakroysky; Daniel Wojdyla; Lisa A Kaltenbach; Matthew W Sherwood; Matthew T Roe; Tracy Y Wang; Eric D Peterson; Hitinder S Gurm; Mauricio G Cohen; John C Messenger; Sunil V Rao
Journal:  Circulation       Date:  2019-01-22       Impact factor: 29.690

4.  The obesity paradox, extreme obesity, and long-term outcomes in older adults with ST-segment elevation myocardial infarction: results from the NCDR.

Authors:  Ian J Neeland; Sandeep R Das; DaJuanicia N Simon; Deborah B Diercks; Karen P Alexander; Tracy Y Wang; James A de Lemos
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2017-07-01

Review 5.  Arterial access and arteriotomy site closure devices.

Authors:  Sunil V Rao; Gregg W Stone
Journal:  Nat Rev Cardiol       Date:  2016-08-25       Impact factor: 32.419

Review 6.  Antiplatelet Therapy in Percutaneous Coronary Intervention.

Authors:  Alexander C Fanaroff; Sunil V Rao
Journal:  Interv Cardiol Clin       Date:  2016-02-13

7.  Percutaneous Coronary Intervention in Older Patients With ST-Segment Elevation Myocardial Infarction and Cardiogenic Shock.

Authors:  Abdulla A Damluji; Karen Bandeen-Roche; Carol Berkower; Cynthia M Boyd; Mohammed S Al-Damluji; Mauricio G Cohen; Daniel E Forman; Rahul Chaudhary; Gary Gerstenblith; Jeremy D Walston; Jon R Resar; Mauro Moscucci
Journal:  J Am Coll Cardiol       Date:  2019-04-23       Impact factor: 24.094

8.  Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention.

Authors:  Eitan A Friedman; Luisa Texeira; Jessica Delaney; Peter E Weeke; Donald R Lynch; Ehab Kasasbeh; Yanna Song; Frank E Harrell; Josh C Denny; Heidi E Hamm; Dan M Roden; John H Cleator
Journal:  J Thromb Thrombolysis       Date:  2016-05       Impact factor: 2.300

9.  Validating the use of registries and claims data to support randomized trials: Rationale and design of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study.

Authors:  Jordan B Strom; Hector Tamez; Yuansong Zhao; Linda R Valsdottir; Jeptha Curtis; J Matthew Brennan; Changyu Shen; Jeffrey J Popma; Laura Mauri; Robert W Yeh
Journal:  Am Heart J       Date:  2019-03-06       Impact factor: 4.749

10.  Risk-treatment paradox in the selection of transradial access for percutaneous coronary intervention.

Authors:  Neil J Wimmer; Frederic S Resnic; Laura Mauri; Michael E Matheny; Thomas C Piemonte; Eugene Pomerantsev; Kalon K L Ho; Susan L Robbins; Howard M Waldman; Robert W Yeh
Journal:  J Am Heart Assoc       Date:  2013-05-24       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.